Mark Ragosa

CIK: 0001835458

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)26 (25.5%)

Position reduction

Option Exercises (M)48 (47.1%)

Derivative conversions

Awards (A)16 (15.7%)

Compensation grants

Other (G, F, J, C, D, …)12 (11.8%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

KNSA

Kiniksa Pharmaceuticals International, plc

Discretionary Trading P&L

Holdings

Transaction History (102 total)

KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Exercise(M)
Direct
9.6K shares at avg. $10.76$104K
KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Sale(S)
Direct
14K shares at avg. $91.40$1.3M
KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Sale(S)
Direct
12K shares at avg. $93.13$1.1M
KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Exercise(M)
Direct
12.1K shares at avg. $11.97$145K
KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Sale(S)
Direct
10.5K shares at avg. $92.03$966K
KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Exercise(M)
Direct
9.6K shares at avg. $17.76$171K
KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Exercise(M)
Direct
5.4K shares at avg. $11.10$60K
KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Sale(S)
Direct
220 shares at avg. $94.01$21K
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Exercise(M)
Direct
2.7K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Tax Payment(F)
Direct
4.4K shares at avg. $79.28$349K
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Award(A)
Restricted Share Unit
Direct
7.8K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Exercise(M)
Direct
3.1K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Exercise(M)
Direct
1.6K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Exercise(M)
Direct
1.8K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Award(A)
Share Option
Direct
31.2K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Apr 7, 2026
Tax Payment(F)
Direct
1.3K shares at avg. $48.94$64K
KNSA
Kiniksa Pharmaceuticals International, plc
Apr 7, 2026
Exercise(M)
Direct
2.7K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Apr 1, 2026
Award(A)
Share Option
Direct
31.2K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Apr 1, 2026
Exercise(M)
Direct
5.2K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Apr 1, 2026
Award(A)
Performance Share Unit
Direct
15.6K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Apr 1, 2026
Tax Payment(F)
Direct
2.5K shares at avg. $48.13$121K
KNSA
Kiniksa Pharmaceuticals International, plc
Apr 1, 2026
Award(A)
Restricted Share Unit
Direct
7.8K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Mar 9, 2026
Exercise(M)
Direct
2K shares at avg. $22.89$47K
KNSA
Kiniksa Pharmaceuticals International, plc
Mar 9, 2026
Exercise(M)
Direct
13.8K shares at avg. $18.06$249K
KNSA
Kiniksa Pharmaceuticals International, plc
Mar 9, 2026
Exercise(M)
Direct
10.5K shares at avg. $17.76$187K

		Type	Shares	Price		Ownership
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	9,636	$10.76	$103,683	Direct
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	14,027	$91.40	$1,282,068	Direct
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	12,034	$93.13	$1,120,726	Direct
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	12,123	$11.97	$145,112	Direct
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	10,502	$92.03	$966,499	Direct
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	9,636	$17.76	$171,135	Direct
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	5,388	$11.10	$59,807	Direct
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	220	$94.01	$20,682	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	2,694	-	$0	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Tax Payment(F)	4,404	$79.28	$349,149	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Award(A) Restricted Share Unit	7,800	-	-	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	3,069	-	$0	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	1,591	-	$0	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	1,750	-	$0	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Award(A) Share Option	31,150	-	-	Direct
Apr 7, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Tax Payment(F)	1,303	$48.94	$63,769	Direct
Apr 7, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	2,694	-	$0	Direct
Apr 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Award(A) Share Option	31,150	-	-	Direct
Apr 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	5,187	-	$0	Direct
Apr 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Award(A) Performance Share Unit	15,600	-	-	Direct
Apr 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Tax Payment(F)	2,510	$48.13	$120,806	Direct
Apr 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Award(A) Restricted Share Unit	7,800	-	-	Direct
Mar 9, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	2,036	$22.89	$46,604	Direct
Mar 9, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	13,813	$18.06	$249,463	Direct
Mar 9, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	10,513	$17.76	$186,711	Direct

1-25 of 102 transactions

About Ragosa Mark

Ragosa Mark (SEC CIK 0001835458) files insider reports with the SEC as CHIEF FINANCIAL OFFICER of Kiniksa Pharmaceuticals International, plc (KNSA).

Signal8 holds 24 ownership filings by Ragosa Mark, all Form 4s, filed between Sep 4, 2024 and Nov 3, 2026. Those filings report 102 transactions, from Sep 1, 2024 to Nov 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Ragosa Mark's filings is in LONDON.

Recent filings by Ragosa Mark

Nov 2, 2026: Option exercise of KNSA shares (Form 4, code M).
Nov 2, 2026: Open-market sales of KNSA shares (2 lines, Form 4, code S).
Nov 2, 2026: Option exercise of KNSA shares (Form 4, code M).
Nov 2, 2026: Open-market sale of KNSA shares (Form 4, code S).
Nov 2, 2026: Option exercises of KNSA shares (2 lines, Form 4, code M).

Other insiders filing for Kiniksa Pharmaceuticals International, plc (KNSA)

Patel Sanj K, CHAIRMAN & CEO
Paolini John F., CHIEF MEDICAL OFFICER
Moat Ross, CHIEF OPERATING OFFICER
Megna Michael R, CHIEF ACCOUNTING OFFICER
Quart Barry D, Director
Levy Richard S, Director

How to read Form 4 transaction codes